Needham downgrades Biogen on slow growth of Alzheimer's drug

By Yahoo! Finance | Nov 18, 2024 at 11:42 AM EST

Needham downgraded Biogen Inc due to slower growth of Alzheimer's drug, Leqembi, and lack of major catalysts in the next year. The brokerage reduced revenue estimates for Leqembi and mentioned potential stock boosts from business deals and upcoming drug data.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.